Yes agreed, the strengths far outweigh any costs (by us). It is a really good development for the company. I always maintained the clinical aspects of the coy has been very sound, but the PR is what has been lacking.
RGS Price at posting:
11.0¢ Sentiment: Hold Disclosure: Held